Treatment of walking impairment in multiple sclerosis with dalfampridine

The Multiple Sclerosis Functional Composite: A clinically meaningful measure of disability

(2015) C. H. Polman et al.   NEUROLOGY

Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis

(2010) Howard L. Zwibel   ADVANCES IN THERAPY

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

(2010) Andrew D. Goodman et al.   ANNALS OF NEUROLOGY

Real-life walking impairment in multiple sclerosis: preliminary comparison of four methods for processing accelerometry data

(2010) Jacob J Sosnoff et al.   Multiple Sclerosis Journal

Walking speed and economic outcomes for walking-impaired patients with multiple sclerosis

(2010) Joshua T Cohen   Expert Review of Pharmacoeconomics & Outcomes Research

The effect of walking mobility on the measurement of physical activity using accelerometry in multiple sclerosis

(2009) Erin M Snook et al.   CLINICAL REHABILITATION

Sustained-release fampridine for multiple sclerosis

(2009) Christopher T Bever et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

(2009) Andrew D Goodman et al.   LANCET

10 Questions About 4-Aminopyridine and the Treatment of Multiple Sclerosis

(2009) Christopher T. Bever   NEUROLOGIST

Community ambulation in patients with chronic stroke: how is it related to gait speed?

(2008) IG van de Port et al.   ACTA DERMATO-VENEREOLOGICA

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Dose comparison trial of sustained-release fampridine in multiple sclerosis

(2008) A. D. Goodman et al.   NEUROLOGY

Confirmation and extension of the validity of the Multiple Sclerosis Walking Scale-12 (MSWS-12)

(2007) Robert W. Motl et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES